Novo Nordisk A/S Peer Comparison

Metric Value Ranking
Market Cap $581.9 Billion 1/21 NVO
$581.9B		 VRTX
$127.0B		 REGN
$115.3B		 MRNA
$46.1B		 SGEN
$43.2B		 ALNY
$30.1B		 BNTX
$20.1B		 BMRN
$16.3B		 SRPT
$13.9B		 RETA
$6.6B		 MDGL
$6.0B		 CRSP
$4.9B		 TGTX
$3.2B		 NTLA
$2.6B		 NVAX
$2.4B		 CVAC
$834.4M		 DNA
$822.4M		 ICPT
$794.7M		 TERN
$582.7M		 HEPA
$4.6M		 CWBR
$755,802
Gross Margin 85% 8/21 ICPT
100%		 RETA
96%		 TGTX
91%		 NTLA
91%		 SRPT
88%		 VRTX
87%		 ALNY
87%		 NVO
85%		 REGN
83%		 BMRN
79%		 SGEN
75%		 BNTX
68%		 NVAX
48%		 DNA
42%		 MRNA
21%		 MDGL
0%		 CWBR
0%		 HEPA
0%		 TERN
0%		 CRSP
-100%		 CVAC
-100%
Profit Margin 39% 3/21 RETA
100%		 VRTX
41%		 NVO
39%		 REGN
23%		 BMRN
14%		 SRPT
9%		 MDGL
0%		 CWBR
0%		 HEPA
0%		 TERN
0%		 ICPT
-3%		 ALNY
-13%		 TGTX
-17%		 SGEN
-33%		 NVAX
-100%		 NTLA
-100%		 CRSP
-100%		 MRNA
-100%		 BNTX
-100%		 CVAC
-100%		 DNA
-100%
EBITDA margin 54% 1/21 NVO
54%		 VRTX
44%		 REGN
28%		 BMRN
17%		 SRPT
16%		 ICPT
-3%		 ALNY
-6%		 TGTX
-14%		 SGEN
-34%		 MDGL
-100%		 CWBR
-100%		 HEPA
-100%		 TERN
-100%		 NVAX
-135%		 BNTX
-154%		 RETA
-356%		 CVAC
-370%		 DNA
-384%		 NTLA
-385%		 MRNA
-737%		 CRSP
-26935%
Quarterly Revenue $9.6 Billion 1/21 NVO
$9.6B		 REGN
$3.1B		 VRTX
$2.7B		 BMRN
$648.8M		 SGEN
$648.7M		 ALNY
$494.3M		 SRPT
$413.5M		 BNTX
$206.2M		 MRNA
$167.0M		 NVAX
$93.9M		 ICPT
$88.8M		 TGTX
$63.5M		 DNA
$37.9M		 NTLA
$28.9M		 CVAC
$24.2M		 RETA
$22.7M		 CRSP
$504,000		 MDGL
$0		 CWBR
$0		 HEPA
$0		 TERN
$0
Quarterly Earnings $3.7 Billion 1/21 NVO
$3.7B 		VRTX
$1.1B 		REGN
$722.0M 		RETA
$193.0M 		BMRN
$88.7M 		SRPT
$36.1M 		ICPT
-$2.8M 		HEPA
-$2.9M 		CWBR
-$4.3M 		TGTX
-$10.7M 		TERN
-$22.4M 		ALNY
-$65.9M 		CVAC
-$92.8M 		NTLA
-$107.4M 		CRSP
-$116.6M 		MDGL
-$147.5M 		NVAX
-$147.6M 		DNA
-$165.9M 		SGEN
-$215.8M 		BNTX
-$346.3M 		MRNA
-$1.2B
Quarterly Free Cash Flow $782.4 Billion 3/21 REGN
$1.4B 		VRTX
$1.1B 		NVO
$782.4M 		CRSP
$109.0M 		BMRN
$12.9M 		ICPT
$3.9M 		CWBR
-$1.8M 		HEPA
-$3.6M 		TGTX
-$8.2M 		TERN
-$22.8M 		CVAC
-$58.8M 		RETA
-$70.2M 		SGEN
-$79.8M 		NVAX
-$90.8M 		ALNY
-$94.5M 		DNA
-$96.0M 		NTLA
-$123.2M 		MDGL
-$149.5M 		SRPT
-$284.5M 		BNTX
-$499.1M 		MRNA
-$1.2B
Trailing 4 Quarters Revenue $36.0 Billion 2/21 BMRN
$1.2T		 NVO
$36.0B		 REGN
$13.1B		 VRTX
$10.2B		 MRNA
$5.2B		 BNTX
$3.0B		 SGEN
$2.3B		 ALNY
$2.0B		 SRPT
$1.4B		 NVAX
$831.7M		 ICPT
$317.7M		 TGTX
$289.3M		 CRSP
$270.5M		 DNA
$208.7M		 CVAC
$58.4M		 NTLA
$52.6M		 RETA
$24.4M		 MDGL
$0		 CWBR
$0		 HEPA
$0		 TERN
$0
Trailing 4 Quarters Earnings $13.2 Billion 2/21 NVO
$9.6B 		REGN
$3.1B 		VRTX
$2.7B 		BMRN
$648.8M 		SGEN
$648.7M 		ALNY
$494.3M 		SRPT
$413.5M 		BNTX
$206.2M 		MRNA
$167.0M 		NVAX
$93.9M 		ICPT
$88.8M 		TGTX
$63.5M 		DNA
$37.9M 		NTLA
$28.9M 		CVAC
$24.2M 		RETA
$22.7M 		CRSP
$504,000 		MDGL
-$0 		CWBR
-$0 		HEPA
-$0 		TERN
-$0
Quarterly Earnings Growth 28% 10/21 RETA
362% 		SRPT
107% 		HEPA
79% 		BMRN
74% 		TGTX
72% 		ALNY
62% 		VRTX
57% 		NVAX
50% 		CVAC
34% 		NVO
28% 		DNA
19% 		TERN
-4% 		REGN
-12% 		SGEN
-13% 		NTLA
-16% 		CWBR
-59% 		MDGL
-90% 		ICPT
-101% 		CRSP
-120% 		BNTX
-163% 		MRNA
-1587%
Annual Earnings Growth 47% 7/21 BMRN
152667% 		TGTX
121% 		SRPT
102% 		RETA
72% 		ALNY
58% 		NVAX
53% 		NVO
47% 		CRSP
44% 		VRTX
27% 		CVAC
5% 		CWBR
1% 		NTLA
-10% 		REGN
-13% 		HEPA
-14% 		DNA
-17% 		SGEN
-26% 		MDGL
-30% 		TERN
-32% 		BNTX
-98% 		ICPT
-124% 		MRNA
-233%
Quarterly Revenue Growth 22% 8/21 RETA
2885% 		TGTX
713% 		NTLA
130% 		CVAC
88% 		SRPT
63% 		ALNY
55% 		SGEN
27% 		NVO
22% 		NVAX
16% 		ICPT
14% 		VRTX
13% 		BMRN
9% 		MDGL
0% 		CWBR
0% 		HEPA
0% 		TERN
0% 		REGN
-1% 		DNA
-53% 		BNTX
-85% 		MRNA
-91% 		CRSP
-99%
Annual Revenue Growth 24% 7/21 BMRN
56156% 		TGTX
3497% 		RETA
596% 		CRSP
170% 		ALNY
51% 		SRPT
36% 		NVO
24% 		CVAC
17% 		SGEN
15% 		VRTX
10% 		ICPT
8% 		MDGL
0% 		CWBR
0% 		HEPA
0% 		TERN
0% 		NTLA
-1% 		REGN
-2% 		NVAX
-12% 		DNA
-44% 		MRNA
-70% 		BNTX
-81%
Cash On Hand $932.7 Million 5/21 BNTX
$9.9B 		VRTX
$9.2B 		REGN
$2.6B 		MRNA
$2.1B 		NVO
$932.7M 		DNA
$843.8M 		BMRN
$747.0M 		CRSP
$707.4M 		ALNY
$681.9M 		MDGL
$622.5M 		NVAX
$491.0M 		CVAC
$442.6M 		SGEN
$428.6M 		SRPT
$427.3M 		NTLA
$172.0M 		ICPT
$102.7M 		TGTX
$75.5M 		TERN
$65.1M 		RETA
$48.8M 		HEPA
$13.1M 		CWBR
$6.2M
Short Term Debt $1.5 Billion 1/21 NVO
$1.5B 		BMRN
$494.4M 		SRPT
$105.6M 		ALNY
$87.8M 		BNTX
$34.4M 		MRNA
$25.0M 		NTLA
$18.8M 		CRSP
$16.0M 		NVAX
$6.3M 		CVAC
$5.5M 		RETA
$2.5M 		TGTX
$1.4M 		MDGL
$542,000 		TERN
$427,000 		HEPA
$134,020 		REGN
$1 		VRTX
-$0 		SGEN
-$0 		ICPT
-$0 		CWBR
-$0 		DNA
-$0
Long Term Debt $2.5 Billion 1/21 NVO
$2.5B		 ALNY
$2.4B		 REGN
$2.0B		 MRNA
$1.2B		 SRPT
$1.1B		 VRTX
$721.3M		 BMRN
$593.6M		 DNA
$234.5M		 BNTX
$225.3M		 ICPT
$223.9M		 CRSP
$218.9M		 NVAX
$168.4M		 RETA
$163.5M		 MDGL
$116.1M		 SGEN
$113.5M		 TGTX
$101.3M		 NTLA
$92.1M		 HEPA
$41,248		 CWBR
$0		 CVAC
$0		 TERN
$0
PE 44.19 4/21 SRPT
825.47		 BNTX
162.11		 TGTX
77.16		 NVO
44.19		 VRTX
31.60		 REGN
29.89		 BMRN
0.21		 NVAX
-1.00		 ALNY
-1.00		 RETA
-1.00		 SGEN
-1.00		 ICPT
-1.00		 MDGL
-1.00		 NTLA
-1.00		 CRSP
-1.00		 CWBR
-1.00		 HEPA
-1.00		 MRNA
-1.00		 CVAC
-1.00		 TERN
-1.00		 DNA
-1.00
PS 109.52 2/21 RETA
269.17		 NVO
109.52		 NTLA
48.60		 SGEN
18.76		 CRSP
18.07		 ALNY
15.02		 CVAC
12.99		 VRTX
12.48		 TGTX
10.99		 SRPT
9.94		 MRNA
8.95		 REGN
8.80		 BNTX
6.11		 DNA
3.94		 NVAX
2.89		 ICPT
2.50		 BMRN
0.01		 MDGL
-1.00		 CWBR
-1.00		 HEPA
-1.00		 TERN
-1.00
PB 39.89 2/21 RETA
75.22		 NVO
39.89		 TGTX
19.85		 SGEN
16.92		 SRPT
14.51		 ICPT
11.06		 MDGL
7.10		 VRTX
6.85		 REGN
4.27		 MRNA
3.60		 BMRN
3.20		 NTLA
2.47		 TERN
2.46		 CRSP
2.35		 CVAC
1.47		 BNTX
0.92		 DNA
0.83		 HEPA
0.62		 CWBR
0.08		 NVAX
0.00		 ALNY
0.00
PC 623.85 1/21 NVO
623.85		 RETA
134.44		 SGEN
100.70		 REGN
44.32		 ALNY
44.13		 TGTX
42.12		 SRPT
32.64		 MRNA
22.31		 BMRN
21.76		 NTLA
14.87		 VRTX
13.87		 MDGL
9.70		 TERN
8.95		 ICPT
7.74		 CRSP
6.91		 NVAX
4.89		 BNTX
2.04		 CVAC
1.89		 DNA
0.97		 HEPA
0.35		 CWBR
0.12
Liabilities to Equity 2.02 4/21 RETA
4.76		 ICPT
4.47		 SRPT
2.35		 NVO
2.02		 TGTX
1.33		 HEPA
1.13		 DNA
0.60		 CVAC
0.52		 SGEN
0.42		 BMRN
0.35		 CWBR
0.32		 MRNA
0.31		 VRTX
0.29		 REGN
0.27		 MDGL
0.27		 NTLA
0.22		 CRSP
0.17		 BNTX
0.11		 TERN
0.04		 NVAX
0.00		 ALNY
0.00
ROA 0.04 5/21 BMRN
1114% 		VRTX
17% 		REGN
11% 		TGTX
11% 		NVO
4% 		SRPT
1% 		BNTX
1% 		ALNY
-9% 		CRSP
-9% 		ICPT
-15% 		RETA
-16% 		SGEN
-21% 		NVAX
-29% 		MRNA
-36% 		CVAC
-36% 		TERN
-37% 		NTLA
-39% 		MDGL
-41% 		DNA
-54% 		CWBR
-99% 		HEPA
-241%
ROE 0.13 7/21 BMRN
1509% 		ALNY
151% 		NVAX
46% 		TGTX
26% 		VRTX
22% 		REGN
14% 		NVO
13% 		SRPT
2% 		BNTX
1% 		CRSP
-10% 		SGEN
-29% 		TERN
-38% 		NTLA
-47% 		MRNA
-47% 		MDGL
-52% 		CVAC
-55% 		ICPT
-82% 		DNA
-86% 		RETA
-94% 		CWBR
-131% 		HEPA
-512%
Current Ratio 1.49 16/21 TERN
24.56		 BNTX
9.73		 CRSP
6.87		 NTLA
5.64		 MDGL
4.67		 REGN
4.66		 VRTX
4.45		 MRNA
4.28		 CWBR
4.17		 BMRN
3.82		 SGEN
3.35		 CVAC
2.91		 DNA
2.66		 HEPA
1.89		 TGTX
1.75		 NVO
1.49		 SRPT
1.42		 ICPT
1.22		 RETA
1.21		 ALNY
0.95		 NVAX
0.61
Quick Ratio 0.05 21/21 SRPT
825.47		 BNTX
162.11		 TGTX
77.16		 NVO
44.19		 VRTX
31.60		 REGN
29.89		 BMRN
0.21		 NVAX
-1.00		 ALNY
-1.00		 RETA
-1.00		 SGEN
-1.00		 ICPT
-1.00		 MDGL
-1.00		 NTLA
-1.00		 CRSP
-1.00		 CWBR
-1.00		 HEPA
-1.00		 MRNA
-1.00		 CVAC
-1.00		 TERN
-1.00		 DNA
-1.00
Long Term Debt to Equity 0.17 6/21 ICPT}
3.12		 RETA}
1.87		 SRPT}
1.18		 TGTX}
0.63		 DNA}
0.24		 NVO}
0.17		 MDGL}
0.14		 BMRN}
0.12		 CRSP}
0.11		 NTLA}
0.09		 MRNA}
0.09		 REGN}
0.07		 VRTX}
0.04		 SGEN}
0.04		 HEPA}
0.01		 BNTX}
0.01		 CWBR}
0.00		 CVAC}
0.00		 TERN}
0.00		 NVAX}
-0.19		 ALNY}
-10.76
Debt to Equity 0.27 5/21 ICPT
3.12		 RETA
1.90		 SRPT
1.44		 TGTX
0.70		 NVO
0.27		 DNA
0.24		 BMRN
0.21		 MDGL
0.14		 NTLA
0.11		 CRSP
0.11		 REGN
0.10		 MRNA
0.10		 CVAC
0.08		 VRTX
0.04		 SGEN
0.04		 HEPA
0.02		 BNTX
0.01		 CWBR
0.00		 TERN
0.00		 NVAX
-0.26		 ALNY
-12.24
Burn Rate -11.80 21/21 BNTX
24.78		 BMRN
12.73		 SRPT
11.99		 ICPT
8.75		 CRSP
5.47		 TGTX
5.00		 DNA
4.81		 HEPA
4.54		 CVAC
4.28		 MDGL
4.09		 ALNY
3.74		 NVAX
3.15		 TERN
2.90		 SGEN
1.95		 MRNA
1.68		 NTLA
1.49		 CWBR
1.43		 RETA
-0.26		 REGN
-4.05		 VRTX
-8.55		 NVO
-11.80
Cash to Cap 0.00 21/21 CWBR
8.19		 HEPA
2.82		 DNA
1.03		 CVAC
0.53		 BNTX
0.49		 NVAX
0.20		 CRSP
0.14		 ICPT
0.13		 TERN
0.11		 MDGL
0.10		 VRTX
0.07		 NTLA
0.07		 BMRN
0.05		 MRNA
0.04		 SRPT
0.03		 ALNY
0.02		 REGN
0.02		 TGTX
0.02		 RETA
0.01		 SGEN
0.01		 NVO
0.00
CCR 0.21 16/21 REGN
1.87		 BNTX
1.44		 ALNY
1.43		 HEPA
1.27		 NTLA
1.15		 TERN
1.02		 MDGL
1.01		 MRNA
1.01		 VRTX
0.96		 TGTX
0.77		 CVAC
0.63		 NVAX
0.62		 DNA
0.58		 CWBR
0.42		 SGEN
0.37		 NVO
0.21		 BMRN
0.15		 RETA
-0.36		 CRSP
-0.94		 ICPT
-1.38		 SRPT
-7.88
EV to EBITDA 3.01 5/21 SRPT}
231.16		 BMRN}
151.93		 REGN}
132.28		 VRTX}
99.70		 NVO}
3.01		 MDGL}
-1.00		 CWBR}
-1.00		 HEPA}
-1.00		 TERN}
-1.00		 DNA}
-1.46		 CVAC}
-6.84		 NVAX}
-16.91		 NTLA}
-22.38		 CRSP}
-32.53		 MRNA}
-36.84		 BNTX}
-46.33		 RETA}
-82.50		 SGEN}
-191.83		 ICPT}
-331.82		 TGTX}
-349.93		 ALNY}
-1072.68
EV to Revenue 2.95 13/21 RETA
273.97		 NTLA
47.44		 SGEN
18.62		 CRSP
16.33		 ALNY
16.02		 VRTX
11.65		 TGTX
11.11		 SRPT
10.62		 CVAC
9.51		 REGN
8.81		 MRNA
8.79		 BNTX
4.46		 NVO
2.95		 ICPT
2.88		 NVAX
2.57		 DNA
1.02		 BMRN
0.01		 MDGL
-1.00		 CWBR
-1.00		 HEPA
-1.00		 TERN
-1.00

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions